title: Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
abstract: Ocriplasmin is a recombinant protease approved as a nonsurgical treatment for vitreomacular traction (VMT) and small macular holes with vitreomacular adhesion (VMA). Successful ocriplasmin treatment in clinical studies has been defined as nonsurgical resolution of VMA as demonstrated on optical coherence tomography (OCT) by day 28 after intravitreal injection. This report presents three eyes with improvement in visual acuity and clinical symptoms despite only partial release of VMT over 28 days after ocriplasmin injection.
authors.forename: Karen W
authors.initials: KW
authors.lastname: Jeng
authors.forename: Caroline R
authors.initials: CR
authors.lastname: Baumal
authors.forename: Andre J
authors.initials: AJ
authors.lastname: Witkin
authors.forename: Steve R
authors.initials: SR
authors.lastname: Witkin
authors.forename: Torsten W
authors.initials: TW
authors.lastname: Wiegand
authors.forename: Nadia K
authors.initials: NK
authors.lastname: Waheed
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005128:Eye Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000267:Tissue Adhesions / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body / Q000187:drug effects* / Q000378:metabolism
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin